Pneumonia Vaccine Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Prevnar 13, Synflorix, and Pneumovax 23), By Dosage (Single Dose Vial and Pre-filled Syringe), By End User (Child, Adult and Geriatric), By Vaccine Type (Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine) and Region  

Pneumonia Vaccine Market size was valued at US$ 9.8 billion in 2023, and is poised to grow at a CAGR of 5.6% from 2024-2030. Pneumonia is an illness that results in lung contamination in both the lungs due to bacterial viruses and organisms. Pneumonia irritates the sacs also referred to as the alveoli of the lungs results in breathing problems as the alveoli fill with pus. Pneumococcal illnesses are commonly found in young children but older ones and adults are also more prone to this illness and even death. To get rid of the illness, pneumococcal vaccines are given to children younger than 2 years and adults. Such vaccines give relief from the bacteria, that make the lungs infected by creating immunity in people. This vaccine has the potential to fight against 13 kinds of pneumococcal bacteria causing infection to the lungs. The pneumococcal polysaccharide vaccine is also referred to as Pneumovax 23 (PPV-23). This vaccine is the first pneumococcal vaccine and crucial landmark in medical history derived from a capsular polysaccharide. This vaccine is hugely given to adults who are at high risk. There are two vaccine types available.

A conjugate vaccine contains polysaccharide antigen, which has the potent to improve the vaccine stability and efficacy. This vaccine segment greatly contributes towards the global pneumonia vaccine market growth. Infants and Children of 6 weeks to 5 years of age can take this vaccine for the prevention of pneumonia. However, the longer timetables necessary for the production of pneumococcal vaccines, as well as the greater costs associated with vaccine research, are impeding the market's global expansion. Moreover, throughout the projected period, the development of protein-based vaccines for pneumonia is expected to generate chances for market advancement.